Successful treatment of chronic spontaneous urticaria and bladder pain syndrome with montelukast and/or omalizumab: a case report Authors: Gökten Bulut Published: 2025 ABSTRACT AbstractBackgroundBladder pain syndrome (BPS) is a chronic condition characterized by pelvic pain, frequency, and urgency lasting more than 6 months without a urinary tract infection. It is a devastating condition that affects both sexes and is often confused with other conditions that cause pelvic pain. Diagnosis is difficult, and effective treatment options are limited.Case presentationIn this article, I present a 59 year-old Turkish male patient with chronic spontaneous urticaria with typical clinical symptoms of bladder pain syndrome. Common etiologies that could cause increased urinary frequency, urgency or nocturia, urinary tract infection, and overactive bladder were excluded.ConclusionThe patient’s symptoms improved significantly with omalizumab and montelukast. This case not only provides new insight into the management of BPS, but also highlights the potential roles of mast cell-mediated mechanisms in the etiology and treatment of this complex condition.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13256-025-05549-9.Keywords: Bladder pain syndrome, Chronic spontaneous urticaria, Montelukast, Omalizumab Background Bladder pain syndrome (BPS) is a chronic bladder disorder characterized by urinary urgency and frequency, as well as bladder and pelvic pain [1]. The etiology of BPS remains controversial and has been associated with bacterial infection, mast cell activation, and neurogenic inflammation [2]. Among these factors, mast cell activation may play an important role in the development of BPS because several small molecules that act on mast cells were present in urine samples of patients with BPS, and the current study pointed out that montelukast may be useful in reducing symptoms in a significant percentage of patients with interstitial cystitis in observational studies [3, 4]. BPS affects approximately 3 million American women and costs more than one billion dollars per year in the USA [5]. The International Continence Society (ICS) has defined BPS as the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms, such as increased daytime and nighttime frequency, in the absence of proven urinary infection or other obvious pathology. Since the term “interstitial cystitis” (IC) has different meanings in different centers and different regions of the world, the European Society for the Study of Interstitial Cystitis (ESSIC) has established a consensus on definitions, diagnosis and classification to address the lack of international consensus on the various aspects of IC and has decided to name the disease bladder pain syndrome [6]. BPS is a diagnosis of exclusion, and a careful assessment of symptoms, physical examination, urinalysis, urine culture, pelvic ultrasonography, and cystoscopy is required to differentiate IC/BPS from other causes of these symptoms. The diagnosis of BPS depends mainly on the patient’s subjective symptoms. The O’Leary-Sant Symptom and Problem Index is a symptom screening questionnaire designed for use in practice [7]. The questionnaire consists of four symptom-related questions (max total score of 20) and four problem-related questions (max score of 16). A total score (symptom + problem index) greater than 6 suggests that BPS is possible, and a score greater than 12 is strong evidence in favor of the diagnosis. In our patient, Turkish versions of the interstitial cystitis symptom index (ICSI) and interstitial cystitis problem index (ICPI) were used for use in Turkish-speaking patients with BPS [8]. Turkish versions of ICSI and ICPI are reliable, consistent, and valid instruments to evaluate symptoms of Turkish speaking patients with BPS. Urticaria is defined as the sudden development of transient hives (wheals) and/or angioedema [9]. A wheal is characterized by circumscribed superficial edema of the skin, usually surrounded by bright red erythema and associated with intense itching or a burning sensation. In urticaria, wheals develop within several minutes and, disappearing rapidly (within 30 min to 24 h) without leaving a trace. Various scoring systems are used to determine the severity of urticaria. The most commonly used of these are the urticaria activity score and the urticaria control test. Weekly urticaria activity score (UAS7): 6 and below indicates good control, 7–15 indicates mild severity, 16–27 indicates moderate severity, and 27–42 indicates severe disease [10]. UAS7 is mainly used for the assessment of disease severity. However “urticaria control test (UCT)” which is composed of four simple questions was developed for improving patient compliance and it is a practical tool in the clinical setting. In the urticaria control test, a score of 12 and above indicates well-controlled disease, and a score of 11 and below indicates uncontrolled disease[10]. As first-line therapy, second-generation, non-sedating H1-antihistamines are used. Dose escalation up to fourfold dosage of antihistamines serves as second-line strategy. In case symptoms persist, an add-on of omalizumab, ciclosporin, or montelukast is recommended [9]. Leukotriene receptor antagonists (LTRAs), particularly montelukast, may be used in combination with second line antihistamines in chronic spontaneous urticaria (CSU) due to low side effect profile and being safe[10]. Omalizumab is the effective and safe treatment option approved for patients with CSU whose symptoms persist despite high dose antihistamine treatment [10]. In this study, I report a patient with BPS accompanied by chronic spontaneous urticaria who was successfully treated with montelukast and/or omalizumab (Xolair, Novartis). Montelukast was added to our patient’s current antihistamine treatment for both urticaria and BPS. BPS symptoms significantly regressed, while there was no significant change in urticaria symptoms. Omalizumab treatment was started because the patient had uncontrolled urticaria despite the fourfold increase in antihistamine treatment. Concurrent montelukast treatment was discontinued to evaluate the effect of omalizumab on BPS. Omalizumab was continued for much longer than the time required for montelukast to be eliminated from the body. As a result, a clinically significant improvement in BPS symptoms was seen with both montelukast and omalizumab, but this effects were not independent of the possible placebo effect of either drug. The case I present is the first documented case of BPS treated with montelukast and/or omalizumab in Türkiye, which makes a significant contribution to the global understanding of this syndrome. Additionally, this report is innovative in that it explores a treatment approach involving the use of montelukast or omalizumab, which has previously been extremely rare documented in the literature. This case not only provides a new perspective on the management of BPS, but also highlights the etiology of this complex condition and the potential roles of mast cell-mediated mechanisms. The main goal of BPS treatment is to restore bladder function, prevent recurrence and improve quality of life. There are multiple treatment options for BPS, including dietary therapy, behavioral modification training (BAT), oral medication, intravesical instillation, and surgical intervention [11]. Treatment strategies for BPS are prioritized based on empirical evidence, as the mechanism of this disorder is not yet clear. In the case I present, there was a significant improvement in the clinical symptoms of BPS with montelukast and omalizumab, suggesting that mast cell-targeted therapies may be an option for at least a group of BPS patients. Initially, BPS symptoms improved significantly with montelukast, and then when montelukast was stopped and omelizumab was started, BPS symptoms also almost completely resolved. Documentation of interstitial cystitis and bladder mastocytosis in a patient with chronic urticaria provides support for a patho-physiologic role of mast cells in interstitial cystitis. Case presentation A 58-year-old Turkish male patient had bladder symptoms such as daily frequent urination, urgency, and dysuria, along with occasional lower abdominal and pelvic pain for 3 years. He also complained of mild pelvic pain during sexual intercourse. His urine was sterile on several cultures and his urinalysis was within normal ranges. His symptoms did not respond to nonsteroidal anti-inflammatory drugs or drugs that control gas, bowel, and urogenital motility. There were no fever, appetite changes, bowel habits changes, or any infection-related symptoms. Our patient, who is a urologist, applied to our clinic because his urological tests were normal and he also had urticaria. His daytime urination frequency was more than 20 and his nighttime urination frequency was more than 3. Systemic examination was unremarkable except for suprapubic tenderness. Urinalysis and urine culture were insignificant. Laboratory tests, such as complete blood count, fasting blood sugar, hemoglobin A1c, erythrocyte sedimentation rate, thyroid function tests, liver function tests, prostate specific antigen (PSA), were within normal limits. Skin prick tests and allergen specific immunoglobulin E (IgE) were negative. Pelvic ultrasound and cystoscopy were insignificant. Interstitial cystitis symptom and problem questionnaire total score was 33, which was quite high (max. score 36). Common etiologies that may cause increased urinary frequency, urgency or nocturia, urinary tract infection and overactive bladder were excluded and the patient was diagnosed with BPS. The patient’s medical history revealed that he had chronic urticaria for the last 1 year and was taking antihistamines. Urticaria lesions occurred 20–50 times a day, every day of the week, and the severity of itching was at a level that would not affect daily activities and sleep. With this information, the urticaria activity score (UAS7) was 22 (moderate disease) and the urticaria control test (UCT) score was 8 (uncontrolled). Angioedema accompanied by urticaria only occurred when using non-steroidal anti-inflammatory drugs (NSAIDs). Stress and NSAIDs were triggers, but there was no physical trigger. Our patient did not have an allergic or autoimmune disease that could cause urticaria. The patient’s current antihistamine treatment was increased threefold to control urticaria. Montelukast sodium (10 mg/day) was added to existing antihistamine therapy for the treatment of BPS and for the treatment of urticaria exacerbated by NSAIDs. At the 2-week follow-up visit, the patient’s urinary symptoms were significantly reduced and suprapubic pain disappeared. The total score of the interstitial cystitis symptom and problem questionnaire decreased to 9. The patient’s UAS7 score was 10, UCT score was 11, and urticaria was not under control. During follow-up, the patient’s antihistamine dose was increased up to fourfold to control chronic urticaria symptoms, but despite this treatment, the patient’s urticaria could not be controlled. As recommended in the urticaria angioedema guidelines, the patient who did not respond to fourfold antihistamine treatment was planned to receive 6-month omalizumab treatment and no additional laboratory test was requested before treatment. 300 mg omalizumab was injected subcutaneously (150 mg in each arm) every 4 weeks. Montelukast treatment was stopped simultaneously to fully evaluate the effectiveness of omalizumab on BPS. At the 1-month follow-up visit, the total score of the interstitial cystitis symptom and problem questionnaire was 3 and UAS7 was 4 UCT was 14. Our patient reported that his urogenital symptoms and urticaria symptoms disappeared after starting omalizumab treatment (Fig. 1). At the 5 month follow-up visit, the patient is asymptomatic in terms of BPS and urticaria without side effects under omalizumab and antihistamine treatment. Graphical representation of clinical course of the patient Discussion Chronic spontaneous urticaria is defined as the spontaneous appearance of wheals, angioedema or both for at least 6 weeks owing to unknown causes [9]. The documentation of BPS in a patient with chronic urticaria, a disease with known mast cell involvement, lends further credence to the putative role of mast cells in BPS. According to ICS, BPS should definitely be considered in the differential diagnosis of chronic pelvic pain that increases with bladder filling and is accompanied by frequent urination. BPS is a not well-defined condition and its prevalence is increasing, especially among women. This may be due to the inability to clearly differentiate between chronic pelvic pain syndrome, which is a component of prostatitis, and BPS in male patients [12]. On examination, the pelvic floor muscles are often found to be tight and may contain tender trigger points [13]. On cystoscopy, irregular glomerulations are seen and submucosal ulcerations are sometimes noted [2]. Our patient’s cystoscopy was insignificant, and there was mild suprapubic tenderness on examination. A wide array of treatment options exist for BPS, although well-designed clinical trials to evaluate effectiveness are largely lacking [14]. Multimodal therapy that includes pentosan polysulfate sodium (Elmiron), a tricyclic antidepressant, and an antihistamine is a relatively new approach to symptom relief based on advances in understanding of the complementary pathophysiologic mechanisms, but it remains to be evaluated in well-designed clinical effectiveness trials [11, 14]. Inflammation is believed to play a central role in the pathogenesis of BPS. The presence of leukotriene receptors on detrusor muscle cells, increased urinary levels of leukotriene E4 in patients with BPS and detrusor mastocytosis suggest a role for mast cell activation in IC [15]. It is possible that leukotrienes and eosinophil protein X play a role in the pathogenesis of interstitial cystitis. Urinary leukotriene E4 and eosinophil protein X may be useful markers to assess the degree of activation of mast cells and eosinophils and/or to confirm the diagnosis in patients with interstitial cystitis. Leukotriene E4 plays a role in the activation of mast cells and eosinophils. When mast cells are activated, they release vasoactive, inflammatory mediators, such as kinin, leukotrienes, protease, prostaglandins, and nitric oxide, which are important in chronic inflammatory disorders [16]. Mast cells are not only necessary for allergic reactions, but recent findings indicate that they are also involved in a variety of neuroinflammatory diseases, especially those worsened by stress. In these cases, mast cells appear to be activated through their Fc receptors by immunoglobulins other than IgE, as well as by anaphylatoxins, neuropeptides, and cytokines to secrete mediators selectively without overt degranulation [16]. These facts can help us better understand a variety of sterile inflammatory conditions, such as multiple sclerosis, migraines, inflammatory arthritis, atopic dermatitis, coronary inflammation, interstitial cystitis and irritable bowel syndrome, in which mast cells are activated without allergic degranulation. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, has an anti-inflammatory role by inhibiting leukotriene receptors in the bladder, thereby preventing mast cell activation. In a study study, 10 women with IC (who also had detrusor mastocytosis with a minimum of 28 mast cells per mm) received 10 mg of montelukast daily for three months. After 3 months of montelukast treatment, there was a statistically significant decrease in the 24-hour urinary frequency, nocturia, and pain [17]. In our patient, ICPI and ICSI scores decreased significantly after 2 weeks of montelukast treatment. The total score decreased from 33 to 9. The anti-IgE antibody omalizumab has been proven an efficacious and a well-tolerated therapy in patients with CSU refractory to antihistamines. Omalizumab is thought to act through potential mechanisms that include reducing mast cell activation, reversing basopenia, and improving basophil IgE receptor function, reducing the activity of IgG autoantibodies against FcεRI and IgE, reducing the activity of IgE autoantibodies against an antigen or autoantigen, and reducing coagulation abnormalities associated with disease activity [18]. Omalizumab 300 mg every 4 weeks achieves fast responses and sustained effects. Degranulated mastocytosis is reported in a bladder biopsy of a patient with IC and chronic urticaria–angiedema [19]. Bladder biopsy revealed bladder mastocytosis with > 60 mast cells/mm2 (normal < 10) in the detrusor and submucosa. Most of the mast cells were activated and degranulated. Omalizumab may improve symptoms in these patients by inhibiting mast cell activation. In our patient, a significant decrease was observed in ICPI and ICSI scores after 1 month of omelizumab treatment, confirming the effectiveness of omalizumab in such patients. The total score decreased from 33 to 3. There are case reports in literature showing successful treatment of BPS with montelukast and with omelizumab [20, 21]. Our patient had significant improvements in BPS symptoms with both drugs. Results of this case suggest that despite a favorable safety profile, there is limited efficacy evidence to suggest the of label use of montelukast and omelizumab in PBS. Longer duration studies involving larger groups of patients with well-defined study designs are warranted to obtain a more valid and reliable measurement of intervention effects. Conclusion In the context of this case study, the patient diagnosed with BPS was successfully treated with montelukast and/or omalizumab, which may serve as a clue to support their role in BPS treatment, especially in patients with a history of CSU. The prevalence of interstitial cystitis in patients with chronic urticaria is unknown and further study is needed. AI statement The author used AI-assisted technologies (Grammarly and MS Word Editor) in the writing process. These technologies improved the readability and language of the work. Still, they did not replace key authoring tasks such as producing scientific or medical insights, drawing scientific conclusions, or providing clinical recommendations. The authors are ultimately responsible and accountable for the contents of the whole work. Supplementary Information Additional file 1. Acknowledgements I would like to thank, Sevgi Duman for her contributions to the collection of data. Gülçin Eylül Bulut conducted the editorial support of this article. Abbreviations Behavioral modification training Chronic spontaneous urticaria Interstitial cystitis Bladder pain syndrome International continence society Interstitial cystitis problem index Interstitial cystitis symptom index Leukotriene receptor antagonists Non-steroidal antiinfammatory drugs Prostate specific antigen Weekly urticaria activity score Urticaria control test Author contribution The author was responsible for the conception, data collection, literature review, drafting, and critical revision of the manuscript. The author read and approved the final manuscript. Funding There is no specific funding related to this research. Data availability The data supporting this study’s findings are available on request from the corresponding author. The data are not publicly available owing to privacy or ethical restrictions. Declarations Ethics approval and consent to participate All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from the participant. The original article is not under consideration by another publication, and its substance, tables, or figures have not been published previously. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1. Data Availability Statement The data supporting this study’s findings are available on request from the corresponding author. The data are not publicly available owing to privacy or ethical restrictions.